Literature DB >> 14800320

[Experimental and clinical studies of antibody absorption in the prophylaxis and treatment of fetal erythroblastosis].

R SIEGERT, W SPIELMANN, A W SCHWENZER.   

Abstract

Entities:  

Keywords:  ERYTHROBLASTOSIS, FETAL

Mesh:

Substances:

Year:  1950        PMID: 14800320     DOI: 10.1007/bf00985516

Source DB:  PubMed          Journal:  Arch Gynakol        ISSN: 0003-9128


× No keyword cloud information.
  10 in total

1.  [Extraction of Rh haptens from human blood and urine].

Authors:  R SIEGERT; W SPIELMANN
Journal:  Z Gesamte Exp Med       Date:  1950

2.  Rh antigen and hapten; nature of antigen and its isolation from erythrocyte stroma.

Authors:  M CALVIN; R S EVANS
Journal:  Proc Soc Exp Biol Med       Date:  1946-04

3.  The treatment of erythroblastosis fetalis with Rh hapten.

Authors:  J LOUGHREY; B B CARTER
Journal:  Am J Obstet Gynecol       Date:  1948-06       Impact factor: 8.661

4.  Therapy of Erythroblastosis Fetalis with Exchange Transfusion.

Authors:  A S Wiener; I B Wexler; T H Grundfast
Journal:  Bull N Y Acad Med       Date:  1947-04

5.  Treatment of Severe Erythroblastosis by Simultaneous Removal and Replacement of the Blood of the Newborn Infant.

Authors:  H Wallerstein
Journal:  Science       Date:  1946-05-10       Impact factor: 47.728

6.  Rh hapten; its preparation, assay and nature.

Authors:  B B CARTER
Journal:  J Immunol       Date:  1949-01       Impact factor: 5.422

7.  Preliminary report on a substance which inhibits anti-Rh serum.

Authors:  B B CARTER
Journal:  Am J Clin Pathol       Date:  1947-08       Impact factor: 2.493

8.  Analysis of 50 cases of erythroblastosis fetalis.

Authors:  V GINSBERG; F FELDMAN
Journal:  Am J Obstet Gynecol       Date:  1950-03       Impact factor: 8.661

9.  Experiences with Rh hapten.

Authors:  J W GOLDSMITH
Journal:  Am J Obstet Gynecol       Date:  1950-01       Impact factor: 8.661

10.  INVESTIGATIONS ON THE OCCURRENCE OF Rh SUBSTANCES IN AMNIOTIC FLUID.

Authors:  E Witebsky; J F Mohn
Journal:  J Exp Med       Date:  1945-08-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.